

NOVEL SYNTHESIS OF PIPERAZINE RING

5

RELATED APPLICATION

This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional application, Serial No. 60/130,048, filed April 19, 1999.

FIELD OF THE INVENTION


10

The present invention relates to methods for the synthesis of piperazine rings, particularly for the preparation of heterocyclic compounds useful as intermediates in the synthesis of piperazinoazepines such as the antidepressant mirtazapine.

BACKGROUND OF THE INVENTION

15

Mirtazapine, also known as 1,2,3,4,10,14b-hexahydro-2-methylpyrazine [2,1-a]pyrido[2,3-c] benzazepine, is an antidepressant suitable for oral administration. It has a tetracyclic chemical structure unrelated to other classes of antidepressants such as selective serotonin reuptake inhibitors (SSRIs), tricyclics or monoamine oxidase inhibitors. Mirtazapine belongs to the piperazinoazepine group of compounds, and has the following structural formula.




20

Known methods for the preparation of piperazine ring derivatives have low yields (9-30%), expensive reagents, and many reaction steps (Roderick, W.R. et al., J. Med. Chem 9, 1966, 181-185). It is desirable to have methods for preparing piperazine ring derivatives with fewer steps, high yields and inexpensive raw materials.

SUMMARY OF THE INVENTION


The present invention relates to a novel process for preparing a compound of the formula I:



5

wherein

R¹ denotes substituted or unsubstituted alkyl, aryl, arylalkoxy, tosyl, formyl, benzoyl, acetyl or amine; R² denotes substituted or unsubstituted alkyl, alkoxy, aryl, aryloxy or arylalkoxy; and R³ denotes substituted or unsubstituted alkyl, alkoxy, aryl, aryloxy or arylalkoxy; by reacting a compound of the formula



II

10
15

wherein R² and R³ are as defined above and R⁴ and R⁵ are independently selected from the group consisting of fluoro, chloro, bromo and iodo,

with a compound of the formula H₂N-R¹, wherein R¹ is as defined above.


Preferably the reaction is performed in the presence of a solvent. Polar aprotic solvents such as, dimethyl formamide, dimethylacetamide and dimethylsulfoxide are preferred.

20

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a new process for preparing piperazine rings suitable for use in the synthesis of the antidepressant mirtazapine and other tetracyclic compounds such as those disclosed in U.S. Patent No. 4,062,848 to van der Burg, the contents of which are incorporated herein by reference.


The process of the present invention comprises the steps of reacting a compound of formula II:



5

wherein


R⁴ and R⁵ are independently any of the radicals selected from the group that consists of fluoro, chloro, bromo and iodo; and R² and R³ are as defined above;
with a compound of the formula H₂N-R¹, wherein R¹ is as defined above. Preferably, R¹ denotes aryl, acetyl, formyl, benzoyl, amine, or tosyl. Most preferably, R¹ is tosyl. In order to remove any doubt, the tosyl radical is defined as the group of formula VI:




15

wherein Me represents a methyl group. Preferably R² denotes methyl, R³ denotes phenyl, R⁴ denotes chloro, and R⁵ denotes chloro.

Preferably, the compounds of formulae I and II are compounds of formulae IV and V accordingly:




IV




V

In a preferred embodiment, the present invention relates to a process for preparing a compound of formula XI:




XI

wherein Ph represents a phenyl group, which comprises reacting a compound of formula XII:



XII

with a compound of formula XIII:




XIII

Preferably this reaction takes place in the presence of a strong base such as sodium hydroxide (NaOH), sodium hydride (NaH), potassium hydroxide (KOH), potassium hydride (KH), sodium methoxide (NaOMe) and sodium amide (NaNH₂). Sodium hydroxide and sodium hydride are preferred.

Preferred solvents for the above reaction are any one or more of the solvents selected from the group that consisting of dimethyl formamide (DMF), dimethyl acetamide (DMAC), dimethyl sulfoxide (DMSO), xylene, benzene, ethylbenzene, acetonitrile, toluene and ethers with high boiling points such as ethyleneglycol dimethyl ether, diethyleneglycol dimethyl ether, and propyleneglycol dimethyl ether.

The compound of formula XI may be further hydrolyzed to give the compound of formula XIV:




The compound of formula XIV is known as 4-methyl-2-phenylpiperazine. Compounds of formula XI may be hydrolyzed by reacting a compound of the formula XI with acid to give compounds of the formula XIV. Preferred acids for the reaction are strong acids such as sulfuric acid (H₂SO₄), hydrochloric acid (HCl), phosphoric acid (H₃PO₄) and p-toluene sulfonic acid. A more preferred acid is sulfuric acid with a concentration of about 98%.

Preferably the reaction is carried out in aqueous solution.

The compound of formula XIV may be used in the preparation of the mirtazapine (1,2,3,4,10,14b-hexahydro-2-methyl-pyrazino[2,1-a]pyrido[2,3-c][2]benzazepine), as shown in Schemes 1 and 2 below.


Scheme 1



As shown in Scheme 1, the compound 3-cyano-2-(4-methyl-2-phenyl-1-piperazinyl) pyridine may be prepared starting from 2-chloro-3-cyano-pyridine and 4-methyl-2-phenyl-piperazine.

Starting from 3-cyano-2-(4-methyl-2-phenyl-1-piperazinyl)pyridine, mirtazapine can be prepared by two routes, which are further presented in Scheme 2:

Scheme 2




In accordance with the present invention, mirtazapine produced by the process of the present invention may be prepared as pharmaceutical compositions that are particularly useful for the treatment of depression. Such compositions comprise mirtazapine with pharmaceutically acceptable carriers and/or excipients known to one of skill in the art.

EXAMPLES

The following examples are given for the purpose of illustrating the present invention and shall not be construed as being limitations on the scope or spirit of the invention.

5

EXAMPLE 1



A suspension of sodium hydride (60%, 1.1 g) in DMF (20 mL) was prepared. p-Toluenesulfonamide (2.2 g) was dissolved in DMF (10 mL) and added continuously to the sodium hydride suspension. After mixing at room temperature the suspension was heated to 60-70°C.


After that, the solution of beta-chloro-N-methyl-N-chloroethyl phenylethylamine (3 g) in DMF (10 mL) was added dropwise and mixed overnight. The reaction mixture was poured into a mixture of water (21 g) and ice (40 g).

After 4 hours the precipitate was filtered, washed with water (2 x 30 mL) and dried in an oven to give 3.3 g of the product.

20

EXAMPLE 2

Preparation of 4-methyl-2-phenyl piperazine



5

Tosyl piperazine (1.2 g) was dissolved in water (1g) and H₂SO₄ (98%, 3 mL) while heating to 110°C. After 20 minutes at 110-120°C the reaction mixture was poured into water (10 mL) and ice (20 g).

The solution was alkalized to pH 13 with NaOH (47%) and the product was extracted into ether. After phase separation the organic phase was evaporated to dryness to give the 4-methyl-2-phenyl piperazine in 75% yield.

Although certain presently preferred embodiments of the invention have been described herein, it will be apparent to those skilled in the art to which the invention pertains that variations and modifications of the described embodiment may be made without departing from the spirit and scope of the invention. Accordingly, it is intended that the invention be limited only to the extent required by the appended claims and the applicable rules of law.